Search

We developed (GLP-1)-HSA (GGH) analogs that are resistant to degradation and also show high serum glucose-reducing activity in vivo. Five analogs with N-terminal extensions were designed based on the protein GGH. Next, we constructed recombinant plasmids capable of expressing the five analogs in methylotrophic yeast Pichia pastoris GS115. Expression reached 150 mg/L in a small-scale incubation. Fusion proteins were successfully purified from the supernatant using ultrafiltration concentration, affinity absorption chromatography, hydrophobic chromatography, ion exchange chromatography and gel filtration. A single band was observed on SDS-PAGE and the purity was 97%. Activity test results suggested that both A-GGH and G-GGH showed better activity in vitro and that their cAMP levels were significantly increased by 10-fold compared to GGH without N-terminal extension. Additionally, A-GGH efficiently enhanced the glucoselowering effect, which was maintained after the administration for 24 h. A-GGH is a potential drug for treating type 2 diabetes. [ABSTRACT FROM AUTHOR]

This study investigated the effects of hydroxylase cyptochrome P450 inducers on the efficiency of the biotransformation of dehydroepiandrosterone (DHEA) to 3β, 7α, 15α-trihydroxy-5-androsten-17-one (7α,15α-diOHDHEA) by Colletotrichum lini ST-1. Special attention was given to the substrate DHEA being the best inducer and the fact that it could improve the yield of 7α, 15α-diOHDHEA. Based on the effects of the DHEA pre-induction phases and additional concentrations on 7α, 15α-diOHDHEA production, a substrate pre-induction process was established as follows: 2 g/L DHEA was added for the first time after 12 h of inoculation, followed by the second addition of 6 g/L DHEA after 12 h later. The results showed that this substrate pre-induction process improved the content of cytochrome P450 and that the 7α, 15α-diOH-DHEA yield reached 90.1%, which was 26.9% higher than that obtained in the original process. [ABSTRACT FROM AUTHOR]